Ranibizumab Treatment for Retinal Vein Occlusion

Predictive Factors of 2-year Visual Outcome in Retinal Vein Occlusion Following Intravitreal Ranibizumab Treatment

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Inclusion Criteria:

• Signed informed consent form
• Male or female of aged 18 years or older
• Macula edema secondary to BRVO/CRVO
• Decrease of VA due to macular edema

Exclusion Criteria:

• Prior episode of RVO
• Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye)
• Ocular disorders in the study eye that may confound interpretation of study results
• History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO
• The pregnant or lactating woman